Director’s Major Stock Sale Shakes Up ProKidney!

New insider activity at ProKidney ( (PROK) ) has taken place on November 14, 2025.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. Director Brian Jg Pereira has made a significant move by selling 757,162 shares of ProKidney stock, amounting to a total transaction value of $1,883,733. Recent Updates on PROK stock ProKidney has recently presented full results from its Phase 2 REGEN-007 trial, which evaluated the efficacy of rilparencel in patients with advanced chronic kidney disease (CKD) and diabetes. The trial results, presented at the American Society of Nephrology Kidney Week, demonstrated that rilparencel significantly stabilized kidney function, with Group 1 showing a statistically significant 78% improvement in the annual decline of eGFR slope. These findings support the ongoing Phase 3 PROACT 1 study, which aims to bring a novel treatment option to patients with advanced CKD and diabetes. Additionally, ProKidney is conducting a Phase 3 study and a long-term follow-up study to further evaluate the safety and efficacy of its Renal Autologous Cell Therapy (REACT). These developments underscore ProKidney’s potential to lead in renal therapies, potentially boosting its stock performance and investor interest. Spark’s Take on PROK Stock According to Spark, TipRanks’ AI Analyst, PROK is a Underperform. ProKidney’s stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score. To see Spark’s full report on PROK stock, click here. More about ProKidney YTD Price Performance: 31.79% Average Trading Volume: 2,034,677 Technical Sentiment Signal: Buy Current Market Cap: $806.2M